Savolitinib vs. Sunitinib in MET-driven PRCC.
A phase 3 trial of Savolitinib and Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.
Overview
Savolitinib vs. Sunitinib in MET-driven PRCC. is a phase 3 interventional study registered as NCT03091192 by AstraZeneca, with 60 participants enrolled, started 2017-07-25 and due to reach its primary completion in 2019-08-18. Interventions recorded: Savolitinib and Sunitinib. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Shares Savolitinib, Hutchmed, AstraZeneca and the tag pipeline.
- TrialSavolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Shares Savolitinib, AstraZeneca and the tag pipeline.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Savolitinib, AstraZeneca and the tag pipeline.
- TrialA Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Shares Hutchmed and the tag pipeline.
- TrialHMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Shares Hutchmed and the tag pipeline.
- TrialSavolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
Shares Savolitinib, Sunitinib, Renal cell carcinoma, AstraZeneca.
- TrialA Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Shares Hutchmed and the tag pipeline.
- TreatmentHMPL-760
Shares Hutchmed and the tag pipeline.